Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 2/20 | 0.35 |
| ▸ | CDK2 | P24941 | 2/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1451448 | 0.93 | KDM4E (0.33) | CDK1CDK2CCNB1CCNA2CCNA1 | |
| SCHEMBL12630174 | 0.79 | HDAC1 (0.36) | TRPV1 | |
| SCHEMBL1451904 | 0.77 | HDAC1 (0.33) | ALDH1A1TRPV1 | |
| SCHEMBL14794847 | 0.74 | MBOAT4 (0.34) | TRPV1 | |
| SCHEMBL12630167 | 0.72 | TRPV1 (0.32) | TRPV1 | |
| SCHEMBL1450563 | 0.72 | TRPV1 (0.32) | TRPV1 | |
| SCHEMBL31304967 | 0.72 | TRPV1 (0.43) | CDK1CDK2CCNB1CCNA2CCNA1 | |
| SCHEMBL30358873 | 0.71 | MBOAT4 (0.37) | ALDH1A1L3MBTL1TRPV1 | |
| SCHEMBL29192570 | 0.71 | MBOAT4 (0.37) | ALDH1A1L3MBTL1TRPV1 | |
| SCHEMBL1452903 | 0.71 | L3MBTL1 (0.36) | ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383839-B2 | Heterocyclidene acetamide derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-02-26 | — | — | US | disclosed |
| US-20110112071-A1 | NOVEL HETEROCYCLIDENE ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2011-05-12 | — | — | US | disclosed |
| US-20080287428-A1 | Novel Heterocyclidene Acetamide Derivative | MOCHIDA PHARMACEUTICAL CO.,LTD (JP) | 2008-11-20 | — | — | US | disclosed |
| EP-1908753-A1 | NOVEL HETEROCYCLIDENE ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2008-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287428-A1 | Novel Heterocyclidene Acetamide Derivative | TRPV1, TRPV3, TRPA1 | CDK1 500/4885CDK2 382/4885CCNB1 514/4885 |
| US-20110112071-A1 | NOVEL HETEROCYCLIDENE ACETAMIDE DERIVATIVE | TRPV1, TRPV3, TRPA1 | CDK1 500/4885CDK2 382/4885CCNB1 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.